Last reviewed · How we verify

Beclomethasone Dipropionate/Formoterol Fumarate — Competitive Intelligence Brief

Beclomethasone Dipropionate/Formoterol Fumarate (Beclomethasone Dipropionate/Formoterol Fumarate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Beclomethasone Dipropionate/Formoterol Fumarate (Beclomethasone Dipropionate/Formoterol Fumarate) — Alfredo Antonio Chetta. Beclomethasone dipropionate reduces airway inflammation via glucocorticoid receptor activation, while formoterol fumarate bronchodilates by stimulating beta-2 adrenergic receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Beclomethasone Dipropionate/Formoterol Fumarate TARGET Beclomethasone Dipropionate/Formoterol Fumarate Alfredo Antonio Chetta phase 3 Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor
RELVAR/BREO RELVAR/BREO GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+ Symbicort Turbohaler without Turbo+ Istituto per la Ricerca e l'Innovazione Biomedica marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
fluticasone and salmeterol fluticasone and salmeterol University of Chicago marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
FF FF GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor
CHF1535 CHF1535 Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg budesonide/formoterol Turbuhaler 320/9µg AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination class)

  1. Chiesi Farmaceutici S.p.A. · 6 drugs in this class
  2. Alfredo Antonio Chetta · 1 drug in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Sanofi · 1 drug in this class
  5. SkyePharma AG · 1 drug in this class
  6. Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beclomethasone Dipropionate/Formoterol Fumarate — Competitive Intelligence Brief. https://druglandscape.com/ci/beclomethasone-dipropionate-formoterol-fumarate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: